Global Talent Acquisition Partner / Corporate Recruiter
About the job
- At least 5 years of experience in talent acquisition and recruiting, which may come from agency and internal experience; the role is likely unsuitable for someone making a first move in-house from an agency.
- End-to-end experience owning hires across Sales, Commercial, and Go-To-Market, and ability to support hiring across Support, Enablement, and G&A.
- Direct industry experience in a high-growth or rapid-scale organization, ideally in SaaS, software, technology, healthcare, life sciences, or diagnostics.
- Ability to own the end-to-end recruiting experience and independently manage 10–20 requisitions.
- Own corporate hiring in the United States as the local expert, while owning global commercial and go-to-market hiring.
- Partner closely with commercial leaders across the organization to own commercial and go-to-market hiring.
- Support headcount across more than 25 countries and be responsible for global hires.
- Execute sourcing strategies for hard-to-find commercial talent and proactively build talent pipelines for key organizational roles using tools such as Metaview AI Sourcing, Claude Enterprise MCPs, and LinkedIn Recruiter.
- Use market insights to influence data-driven hiring outcomes.
- Drive direct-sourcing channels, improve candidate engagement, and decrease time to hire.
- Support the continuous improvement and sophistication of the talent acquisition agenda, including AI adoption, candidate experience, equity, diversity and inclusion, employee value proposition, and employer brand.
- Previous experience with international or global hiring is beneficial, but may be developed in the role.
Global Talent Acquisition Partner / Corporate Recruiter
SOPHiA GENETICS · Boston, United States (Hybrid) · Full-time · Posted 2026-09-23
Workplace: hybrid
Department: Talent Acquisition
Description
Are you obsessed with exceptional talent, and able to build proactive talent pipelines? Do you want to be responsible for hires with true impact?
If this sounds like you and you are driven by purpose, join the SOPHiA GENETICS Global Talent Acquisition Team as our Corporate Talent Acquisition Partner and enable us to make a positive impact on the outcomes for cancer and rare disease patients worldwide.
Enjoy the flexibility of a hybrid work schedule allowing 2 days per week home working, collaborating closely with our colleagues in our Boston-Fenway corporate office.
Our mission
We believe there is a smarter, more data-driven way to make decisions in healthcare and our cloud-native AI powered SOPHiA DDM Platform makes that vision a reality on a daily basis. You will have direct input to our mission to democratize data-driven medicine for the ultimate benefit of cancer and rare disease patients across the globe.
Your mission
You'll be in a dual focus role, broadly owning all corporate hiring in the US as our local expert, whilst also owning commercial & go-to-market hiring on a global basis,
What you’ll achieve:
- Partner closely with commercial leaders across the organisation to own commercial and go-to-market hiring
- Supporting headcount in 25+ countries, you will have the opportunity to be responsible for hires on a global basis and see direct impact to our ongoing growth by finding the best in-market talent
- Execute sourcing strategies for hard-to-find commercial talent, and proactively build talent pipelines for key organisational roles (powered by tools like Metaview AI Sourcing, Claude Enterprise MCPs and LI Recruiter)
- Use market insights to influence data-driven hiring outcomes
-
Drive positive impact, including direct sourcing channels, improving candidate engagement and decreasing time to hire
-
Bring your passion to support the continuous improvement and sophistication of our TA agenda including AI Adoption, Candidate Experience, ED&I, EVP & Employer Brand
Requirements
We know that every background is different, but to be best set for success we see you bringing:
- 5+ years experience in Talent Acquisition & Recruiting. This can be from both Agency and Internal experience, but this role is likely to be unsuitable for a first move in-house from agency
- You'll have end-to-end experience owning hires across Sales, Commercial and Go-To-Market, but be comfortable supporting wider hiring across Support, Enablement and G&A
- Direct industry experience in a high-growth or rapid-scale organisations, ideally within SaaS/Software/Technology or Healthcare/Life Sciences / Diagnostics
- Previous experience with international / global hiring is beneficial, but this can be a growth point for you
- You'll be comfortable owning the end-to-end experience and managing 10-20 REQs autonomously
- A passion to see talent acquisition as a strategic and value-add function, reinforced with positive, innovative energy
Benefits
You will be joining an organization with the patient at the heart of every decision and action, driven by purpose as we pursue exponential growth.
Business recognition and accolades include:
- World's most innovative companies (Top 10)
- World's smartest companies (Top 50)
- 100 Best Places to Work in Boston
- Top 10 European Tech Startup
- Top 10 European biotechs startup to watch
- Top 25 East-Coast Biotech to watch
Our benefits package is comprehensive, but varies internationally in-line with local standards and laws. You can discuss a full breakdown with us, but as a brief overview:
US:
Outstanding Medical, Dental & Vision with 90% Employer Contribution
Company matched 401K at 4%
Company-paid short & long-term disability insurance
FSA commuter benefits
20 Days PTO, increasing to 25 with tenure; 5 Days Sick and 14 Public Holidays
Free EAP
Our DNA
Like the strands of DNA itself, SOPHiA GENETICS and the team are deeply interconnected and reliant on each other to deliver. There are common threads across the team. Things that bind us together. Those things are Relentless Curious; Resilient & Nimble and Fearlessly Adventurous
Our Virtues
At SOPHiA GENETICS we established our 7 Virtues to clarify how our principles show up each day through action. We Decide; We Do; We Collaborate; We Innovate; We Empower; We Adapt and We Learn.
At the centre of our Virtues is our Mantra, We Care, which provides a constant reminder of the compassionate, benevolent, and hopeful nature of our mission and how it should be threaded through each of our Virtues and everything we do. Learn more about our DNA and Virtues on our Careers portal
The Process
We use the power of AI to help our partners make decisions. If you’re utilizing AI in your search and application process, why not use some of these prompts, or read our AI guide.
‘What impact can I expect to have on the world by working at SOPHiA GENETICS?’
‘I have an interview with SOPHiA GENETICS. What should I know before I meet with them?’
‘I am a *job title* - What can SOPHiA GENETICS offer my career?’
Apply now with your CV and any supporting information.
Suitably qualified candidates will be invited through an interview and screening process where you will speak with members of our Talent Acquisition Team, the hiring leader alongside key colleagues and stakeholders from across the business.
If you need additional support or accommodations for accessibility, please contact our TA team for assistance on [email protected]. SOPHiA GENETICS recruiters only contact candidates from @sophiagenetics.com addresses and never request payment at any stage. Verify any offer before responding.
We appreciate the value external partners can bring, but we operate a direct-hiring model and we are not looking to utilize agency support at this time. All hiring is controlled by Talent Acquisition, potential partners should liaise through TA and not our hiring teams please.
Starting Date: ASAP
Location: Boston, MA - Hybrid 3x/week in office
Contract: Permanent
MA Pay Range: $71,250 - $143,750
Disclaimer: The estimated pay range represents a good faith estimate of what the Company expects to pay a successful applicant for the listed position and applies specifically to candidates based in Massachusetts. Due to various factors, the estimated pay range may vary in other locations. Should the level or location of the role change during the hiring process, the applicable base range may be updated accordingly. Compensation decisions are dependent on several factors including, but not limited to, an individual’s qualifications, job related skills, years of experience, location, relevant education or training, internal equity, and alignment with market data. The range does not include benefits, and if applicable, bonus, commission, or equity.
Apply
Powered by Workable
About the company
Sophia Genetics provides a cloud-based platform called SOPHiA DDM that uses AI and machine learning to analyze digital health data, especially genomic profiles, for healthcare providers, researchers, and pharma companies. It standardizes, computes, and analyzes multimodal data to support diagnosis, therapy selection, analysis, and drug development. Customers own their data and can share insights through the platform, contributing to collective intelligence. The platform is charged on a subscription or access basis, creating a global data-driven medicine ecosystem. The company differentiates itself by enabling data ownership for users, facilitating data sharing among institutions, and handling complex multimodal genomic data to drive better patient outcomes.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Saint-Sulpice, Switzerland
Founded
2011
Get referred to SOPHiA GENETICS
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $23.3 million, growing 27%, with raised guidance to $94-$96 million.
- U.S. revenue rose 64% and liquid biopsy revenue jumped 80% in Q2 2026.
- Synnovis expects roughly 7,000 UK liquid-biopsy tests annually, expanding SOPHiA's installed usage.
What critics are saying
- Guardant Health's UPC and UK patent attacks target SOPHiA's liquid biopsy business.
- June 2026's $50 million offering diluted holders, and another financing looms before profitability.
- If AstraZeneca or MSK programs stall, SOPHiA remains a small, loss-making platform vendor.
What makes SOPHiA GENETICS unique
- SOPHiA DDM spans 1,000-plus institutions across 75 countries, creating a proprietary clinical network.
- AstraZeneca signed two companion-diagnostic programs on August 4, 2026, validating SOPHiA's platform.
- MSK, Synnovis, and MD Anderson partnerships tie elite oncology data to local deployment.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- 401(k) Company Match
- Disability Insurance
- Commuter Benefits
- Paid Vacation
- Paid Sick Leave
- Paid Holidays
- Hybrid Work Options
- Meal Benefits
Growth & Insights and Company News
6 month growth
0%1 year growth
1%2 year growth
1%SOPHiA GENETICS and Myriad Genetics announce new collaboration to advance prostate genomic instability score technology. 08 Oct, 2026, 18:30 IST BOSTON, Oct. 8, 2026 /PRNewswire/ - SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice(R) CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. "This collaboration showcases Myriad's biopharma capabilities to support development of precision oncology treatments," said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. "PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies." As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad's PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS' technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries. "Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world," said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. "By pairing Myriad's world-class biomarker innovation with SOPHiA GENETICS' global network, we are working toward a solution for this. Together, we're building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most." Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM(TM), an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com. SOPHiA GENETICS Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's plans to deploy PrGIS technology, the development of decentralized companion diagnostic solutions, the Company's global commercialization capabilities, and the expected benefits and reach of this collaboration. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties include those described in the Company's Annual Report on Form 20-F filed on March 3, 2026, as well as any updates to those risk factors filed from time to time in the Company's Reports on Form 6-K or other filings with the U.S. Securities and Exchange Commission. SOPHiA GENETICS is not under any obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
SOPHiA GENETICS enters collaboration to develop Companion Diagnostics for precision oncology therapies. Aug 04, 2026, 06:15 ET BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /CNW/ - SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies. As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic. In addition, the company will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer. "A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch. We believe these programs are what that future looks like in practice. Bringing the right therapy to the right patient, in any country and any laboratory, is the work that will define the next generation of precision medicine," said Ross Muken, CEO, SOPHiA GENETICS. By combining accurate biomarker detection with rapid deployment, SOPHiA GENETICS aims to shorten the distance between a new therapy and the patients who need it. Through its global data-driven platform, insights generated from patient populations can help advance informed clinical decision-making across healthcare systems. This vision of connected, data-driven medicine underpins these programs, with the goal of expanding access to innovative treatments and improving outcomes for patients worldwide. About SOPHiA GENETICS Companion Diagnostics SOPHiA GENETICS end-to-end diagnostic capabilities span the drug development and launch continuum: * Clinical Trial Assay (CTA) development, to identify, screen, and enroll the right patients quickly and accurately during a trial. * Companion Diagnostic (CDx) development, validation, and regulatory submission, taking an assay from research use through analytical and clinical validation to approval in the US, EU, Japan, and beyond. * Deployment through the SOPHiA DDM(TM) Platform and the SOPHiA DDM(TM) MaxCare Program, enabling laboratories to bring testing in-house and adopt new genomic applications with confidence, reaching larger populations around the globe. SOPHiA GENETICS's technology-agnostic, cloud-based platform lets healthcare institutions run the same validated, AI-powered analysis locally, while sharing and benefiting from the collective intelligence of a global network of more than 1,000 connected institutions across over 75 countries. For a pharmaceutical partner preparing a global launch, that means a companion diagnostic that can be available in the local lab on day one of drug approval. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM(TM), an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. SOURCE SOPHiA GENETICS Media and Investor Contact: Kellen Sanger, [email protected]; [email protected]
SOPHiA GENETICS reported second quarter 2026 revenue of $23.3 million, up 27% year-over-year. The AI-driven precision medicine company raised its full-year revenue guidance to $94 million to $96 million, representing 22% to 24% growth, up from a prior range of $92 million to $94 million. Net loss remained flat at $22.4 million year-over-year, whilst adjusted EBITDA loss improved 27% to $8.8 million. Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis. The company performed a record 115,000 analyses on its SOPHiA DDM platform, with 60% volume growth in the US and 70% growth in liquid biopsy. SOPHiA GENETICS signed two companion diagnostic programmes with AstraZeneca, its first such partnerships. The company completed an oversubscribed $57.5 million public offering in Q2, bringing cash and cash equivalents to $107.7 million.
SOPHiA GENETICS, a global leader in AI-driven precision medicine, has announced that shareholders at its 2026 Annual General Meeting approved all proposals. Co-founder Dr Jurgi Camblong was elected Executive Chairman of the Board with 99.79% of votes, whilst Ross Muken was elected to the Board with 99.88% and will become CEO effective 1 July 2026. Dr Camblong, who founded the company and served as CEO for 15 years, will focus on long-term strategic, scientific and technological direction. The Board introduced a Lead Independent Director role rotating annually among independent committee chairs. Shareholders also approved the 2025 financial statements, management compensation proposals, and amendments to the Articles of Association. PricewaterhouseCoopers was re-elected as external auditor.
SOPHiA GENETICS announces pricing of $50 million public offering of ordinary shares. Jun 16, 2026, 21:21 ET BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ - SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on June 18, 2026, subject to customary closing conditions. TD Cowen is acting as the lead book-running manager for the offering. Guggenheim Securities is acting as book-running manager, and BTIG and Craig-Hallum are acting as lead managers for the offering. A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares and other securities of the Company has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 15, 2025. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus will be available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained for free by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of SOPHiA GENETICS SA, such as the ordinary shares, in or into Switzerland within the meaning of the Swiss Financial Services Act ("FinSA") and these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland. Neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, may be publicly distributed or otherwise made publicly available in Switzerland. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using Ai to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM(TM), a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our expectations regarding the expected closing of this offering. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the SEC. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements. SOURCE SOPHiA GENETICS